Related Experiment Video
Updated: Sep 12, 2025
08:20
Genome Engineering of Primary Human B Cells Using CRISPR/Cas9
Published on: November 3, 2020
6.4K
Engineering B cells to treat and study human disease
Nikita Trivedi1, Ragan A Pitner1, David J Rawlings1,2
1Seattle Children's Research Institute, Center for Immunity and Immunotherapy, Seattle, WA, USA.
Nature Biotechnology
|August 6, 2025
Summary
Engineered B cell (eB cell) therapies leverage unique B cell properties for treating diseases. Early clinical trials show promise, with ongoing research exploring future applications in cancer and chronic conditions.
Area of Science:
- Immunology
- Cell Therapy
- Biotechnology
Background:
- B cells possess unique immunological features like intercellular communication, protein production, and longevity.
- These characteristics are being exploited for novel therapeutic strategies.
- Engineered B cell (eB cell) therapies represent an emerging frontier in regenerative medicine.
Purpose of the Study:
- To review recent advancements in engineered B cell (eB cell) therapies.
- To summarize early clinical findings and discuss challenges.
- To explore future directions for B cell-based therapeutics.
Main Methods:
- Review of recent scientific literature and early-phase clinical trial data.
- Analysis of B cell biology and its application in therapeutic engineering.
- Discussion of genome editing and animal modeling advancements.
Main Results:
- Significant progress in studying eB cells and conducting proof-of-concept studies.
- Initiation of the first clinical trials for eB cell therapies.
- Identification of key challenges and promising avenues for clinical implementation.
Conclusions:
- Engineered B cell therapies hold significant potential for treating complex diseases.
- Overcoming clinical implementation challenges is crucial for widespread adoption.
- Future applications in oncology and chronic disease management are anticipated.
